TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 234-238

  Suissa, Samy ^a,b   Ernst, Pierre ^a   Hudson, Marie ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

COPD; Drug effectiveness; Etanercept; Infliximab; Observational studies; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; IPRATROPIUM BROMIDE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; INSURANCE CLAIM REVIEW; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38049057089     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.03.003     Document Type: Article

References (24)

1. Lopez A.D., and Murray C.C. The global burden of disease, 1990-2020. Nat Med 4 11 (1998) 1241-1243
2. Gerardi D.A., Lovett L., Benoit-Connors M.L., Reardon J.Z., and Zuwallack R.L. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9 3 (1996) 431-435
3. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 7245 (2000) 1297-1303
4. The lung health study research group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 26 (2000) 1902-1909
5. Keatings V.M., Collins P.D., Scott D.M., and Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153 2 (1996) 530-534
6. Churg A., Wang R.D., Tai H., Wang X., Xie C., and Wright J.L. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 170 5 (2004) 492-498
7. Sakao S., Tatsumi K., Igari H., Shino Y., Shirasawa H., and Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 2 (2001) 420-422
8. Keatings V.M., Cave S.J., Henry M.J., et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 118 4 (2000) 971-975
9. Barnes P.J., and Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 9438 (2004) 985-996
10. Van der Vaart H., Koeter G.H., Postma D.S., Kauffman H.F., and ten Hacken N.H. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 4 (2005) 465-469
11. Rennard S.I., Fogarty C., Kelsen S., et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 926-934
12. Pharmetrics Inc. Pharmetrics patient-centric database 2005. Watertown, MA, USA.
13. Suissa S., Ernst P., Hudson M., Bitton A., and Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 117 2 (2004) 87-92
14. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44 5 (2005) 677-680
15. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B.L. (Ed). Pharmacoepidemiology. 3rd ed (2000), Wiley, New York, NY 785-805
16. Howarth P.H., Babu K.S., Arshad H.S., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 12 (2005) 1012-1018
17. Berry M.A., Hargadon B., Shelley M., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 7 (2006) 697-708
18. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 172 2 (2005) 149-160
19. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 7 (2003) 601-608
20. Jit M., Henderson B., Stevens M., and Seymour R.M. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Rheumatology (Oxford) 44 3 (2005) 323-331
21. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 72 (2005) 46-47
22. Weaver A.L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 43 Suppl 3 (2004) iii17-iii23
23. Chapman K.R., Mannino D.M., Soriano J.B., et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27 1 (2006) 188-207
24. Donaldson G.C., and Wedzicha J.A. COPD exacerbations. 1: epidemiology. Thorax 61 2 (2006) 164-168